Tormod Kyrre Guren - Concepedia

Author

Tormod Kyrre Guren

Also Known As

Mellinghoff, Ingo K, T Guren, T K Guren, T. Guren, T. K. Guren, T.K. Guren, T.K.K. Guren, Tormod K. Guren, Tormod Guren, Tormod K Guren

155

Publications

Citations

H-Index

Concepts

All Affiliations

Oslo University Hospital University of Oslo Uppsala University The Netherlands Cancer Institute Odense University Hospital

About

Tormod Kyrre Guren is an author at Oslo University Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	32	1.3K
2	Health Sciences	8	8	274
3	Cell Biology	6	6	130
4	Cellular Physiology	3	3	91
5	Natural Sciences	1	1	22

Tormod Kyrre Guren

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer Scott Kopetz, Axel Grothey, Rona Yaeger, New England Journal of Medicine	2019	1.4K
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study Kjell Magne Tveit, Tormod Kyrre Guren, Bengt Glimelius, Journal of Clinical Oncology	2012	527
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study Josep Tabernero, Axel Grothey, Eric Van Cutsem, Journal of Clinical Oncology	2021	503
Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer? Svein Dueland, Tormod Kyrre Guren, Morten Hagness, Annals of Surgery	2014	199
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first‐line oxaliplatin‐based treatment Janne B Kjersem, Tone Ikdahl, Tormod Kyrre Guren, Molecular Oncology	2013	143
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity Jarle Bruun, Kushtrim Kryeziu, Peter W. Eide, Clinical Cancer Research	2020	113
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial Jayesh Desai, Guzmán Alonso, Se Hyun Kim, Nature Medicine	2023	106
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings Stefan Kubicka, Richard Greil, Thierry André, Annals of Oncology Gastrointestinal OncologyMedicinePathologyColorectal CancerMetastatic Colorectal Cancer	2013	101
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) Paul Nathan, Paolo A. Ascierto, John B.A.G. Haanen, European Journal of Cancer Translational MedicineMedicineMelanomaIpilimumab TreatmentClinical Trials	2019	97
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial Kjetil Boye, Alessandra Longhi, Tormod Kyrre Guren, Cancer Immunology Immunotherapy	2021	97

Page 1